Melanotan I
Dermatological
Also known as: Afamelanotide, CUV1647, NDP-α-MSH, MT-1, MT1
Synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that promotes melanogenesis for photoprotection research.
- Dose in studies
- 0.5-1 mg per day during loading
- Frequency
- Daily during loading, then maintenance
- Cycle length
- 4-6 weeks loading, then maintenance
- Half-life
- 30 minutes
- Research level
- 4/5 – Well researched
Frequently asked questions about Melanotan I
What is Melanotan I?
Synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that promotes melanogenesis for photoprotection research.
What is the half-life of Melanotan I?
The half-life of Melanotan I is 30 minutes.
What dosage of Melanotan I has been studied?
Described in research: 0.5-1 mg per day during loading, frequency: Daily during loading, then maintenance. This is not a medical recommendation.
How long is a Melanotan I cycle?
Typical cycle length in studies: 4-6 weeks loading, then maintenance.
What are the side effects of Melanotan I?
Nausea: Milder than Melanotan II. Affects ~20-25% of users. Usually mild and transient. Anti-nausea measures rarely needed. · Injection site reactions: Mild redness and soreness. Standard injection site reaction. · Headache: Occasional mild headaches during initial dosing period. · Facial flushing: Mild warmth and redness lasting 30-60 minutes. Less pronounced than with MT-II. · Fatigue: Mild…
How well researched is Melanotan I?
Well researched (4/5). Large phase 3 trials or regulatory approval; long-term data still limited.